TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 14:55 PDT] TG Therapeutics, Inc. (NASDAQ:TGTX), Up By 100% ($37.99) From $37.99 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/29/2025 14:55 PDT] TG Therapeutics, Inc. (NASDAQ:TGTX), Up By 100% ($35.85) From $35.85 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/23/2025 07:36 PDT] TGTX Expected to Trade Up Short Term
• [04/16/2025 07:17 PDT] TGTX Expected to Trade Up After Bullish Patterns Develop
• [04/15/2025 07:45 PDT] TGTX Expected to Trade Up Short Term
• [04/10/2025 07:37 PDT] TGTX Expected to Trade Up After Bullish Patterns Develop
• [04/01/2025 07:35 PDT] TGTX Expected to Trade Up After Bullish Patterns Develop
• [03/14/2025 13:21 PDT] TG Therapeutics, Inc. (NASDAQ:TGTX), Up By 100% ($34.51) From $34.51 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/12/2025 07:09 PDT] TGTX Expected to Trade Up After Bullish Patterns Develop
• [03/07/2025 07:08 PST] TGTX Expected to Trade Down After Bearish Patterns Develop
• [03/06/2025 12:04 PST] TG Therapeutics, Inc. (NASDAQ:TGTX), Up By 100% ($30.94) From $30.94 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/04/2025 07:13 PST] TGTX Expected to Trade Up Short Term
• [02/28/2025 07:09 PST] TGTX Expected to Trade Down Short Term